Breakthrough status for GSK/ Genmab's Arzerra PMLiVE ... to treatment with fludarabine and alemtuzumab since 2009, but sales have been modest - just £60m ($96m) last year for example - as the company has struggled to differentiate its product from Roche's Rituxan/ MabThera (rituximab) in the marketplace. |
